Cystoscopy revealed a papillary tumor
in the prostatic urethra with mild inflammatory changes in the mucosa, which was similar to the information obtained from the nearby clinic (Figure 2).
Primary CIS: isolated CIS with no previous or concurrent papillary tumor
On histopathology, we were surprised to learn that the specimen contained ulcerated squamous epithelium with underlying infiltrating thyroid papillary tumor
cells within the lingual thyroid.
type 1 shows gain of chromosome 2, 7, 12, 16 and 17.
Pediatric pancreatic tumors arise from exocrine or endocrine tissue and include ductal adenocarcinoma, acinar cell carcinoma, pancreatoblastoma, solid pseudo papillary tumor
and endocrine neoplasms.
Histopathology revealed an aggressive papillary tumor
of the middle ear (figure 2, A).
Up until that point SPNs were described by using various other names that should no longer be used to describe this neoplasm, including "solid pseudopapillary tumor," "solid cystic tumor," "papillary cystic tumor," "papillary epithelial neoplasm," "solid and papillary epithelial neoplasm," "papillary epithelial tumor," "Frantz's tumor," "solid and papillary tumor
," "solid-cystic-papillary epithelial neoplasm," benign or malignant papillary tumor
of the pancreas," and adenocarcinoma of the pancreas in childhood.
Aggressive papillary tumor
of the middle ear/temporal bone and adnexal papillary cystadenoma: Manifestations of von Hippel-Lindau disease.
The radiologic appearance of a papillary tumor
on high-resolution CT scan may be partly solid, but a ground-glass opacity also is seen, (8) depending on the amount of air present within the lesion.
Metaplastic papillary tumor
of the fallopian tube also needs to be considered in the differential diagnosis of TIC.
Microscopically, most of the lesion was a papillary tumor
growing in a cystic space.
1) Outcome of patients with a noninvasive papillary tumor
is largely dependent on tumor pathologic grade.
Papillary adenomas are defined as cytologically bland, unencapsulated papillary tumors
measuring less than 15 mm in greatest dimension (B) (hematoxylin-eosin, original magnifications X200 [A] and X40 [B]).
The FDA Fast Track designation will apply to clinical development of ALT-803 in combination with BCG for the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder, as well as for the prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors
following transurethral resection in patients with NMIBC.
which presents as low grade and in early age are less aggressive than nonpapillary tumors--this conventional belief well corroborates with the results of our study.